Analyst Price Targets — RMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 16, 2026 10:26 am | — | RBC Capital | $234.00 | $198.57 | TheFly | ResMed downgraded to Sector Perform from Outperform at RBC Capital |
| July 15, 2026 11:26 am | — | Mizuho Securities | $220.00 | $193.01 | TheFly | ResMed price target lowered to $220 from $235 at Mizuho |
| July 10, 2026 1:06 pm | — | Jefferies | $225.00 | $204.50 | TheFly | ResMed price target lowered to $225 from $240 at Jefferies |
| July 8, 2026 11:43 am | — | RBC Capital | $276.00 | $219.75 | TheFly | ResMed price target lowered to $276 from $321 at RBC Capital |
| July 8, 2026 10:21 am | — | Wells Fargo | $225.00 | $219.75 | TheFly | ResMed price target lowered to $225 from $227 at Wells Fargo |
| June 22, 2026 9:44 am | — | KeyBanc | $266.00 | $188.63 | TheFly | ResMed price target lowered to $266 from $290 at KeyBanc |
| June 17, 2026 8:13 am | David Bailey | Morgan Stanley | $230.00 | $193.94 | StreetInsider | Morgan Stanley Downgrades ResMed (RMD) to Equalweight |
| May 1, 2026 12:52 pm | — | Robert W. Baird | $225.00 | $203.87 | TheFly | ResMed price target lowered to $225 from $254 at Baird |
| April 27, 2026 10:21 am | — | KeyBanc | $290.00 | $219.85 | TheFly | ResMed price target lowered to $290 from $302 at KeyBanc |
| April 13, 2026 2:44 pm | Anthony Petrone | Evercore ISI | $255.00 | $228.33 | TheFly | ResMed price target lowered to $255 from $300 at Evercore ISI |
Latest News for RMD
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.
ResMed Inc. (NYSE:RMD) agreed to sell its MatrixCare business on Tuesday to Frazier Healthcare Partners, a private equity firm focused exclusively on health care, for $490 million.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
I track a curated universe of 50 high-quality dividend growth stocks to identify opportune entry points based on valuation and future return potential. Year-to-date through June, the investable universe returned 8.69%, trailing SPY (10.10%) and SCHD (17.50%), but several individual stocks outperformed significantly. Currently, 39 out of 50 stocks offer a forward return estimate of at least 10%, with 22 appearing…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.